Fundraising Fox
Hepion Pharmaceuticals
OTC: HEPAEdison, US · Founded 2013 · Delaware corporation
Find your way into Hepion Pharmaceuticals
Sign up to see every warm intro you have to Hepion Pharmaceuticals
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Hepion Pharmaceuticals team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Hepion Pharma is a pharmaceutical company with a therapeutic focus on hepatocellular carcinoma (liver cancer). This page is an investor presentations section with no substantive content available.
Founders & leadership
GS
Gary StetzInterim Chief Executive Officer
VL
Vincent LoPrioreExecutive Chairman
BF
Bernard F. DenoyerExecutive
TA
Thomas AdamsNamed on SEC filing
AL
Arnold LippaNamed on SEC filing
GS
Gary S. JacobNamed on SEC filing
RF
Robert FosterNamed on SEC filing
SA
Sireesh AppajosyulaNamed on SEC filing
CL
Chase LoPrioreNamed on SEC filing
DF
Dania FisherNamed on SEC filing
GS
Gary S. Stetz, IINamed on SEC filing
Reported raises · per SEC filings
Form D private placements$49.9M disclosed across 9 rounds · 2014–2026
▶$3.1MraisedAug 2026 · 33 investors · BiotechnologyRule 506(b)
▶$3.1MraisedAug 2026 · 33 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gary StetzExecutive Officer, Director
- Vincent LoPrioreExecutive Officer, Director
- Sireesh AppajosyulaDirector
- Chase LoPrioreDirector
- Michael PurcellDirector
- Dania FisherDirector
- Gary S. Stetz, IIDirector
- Offering amount
- $3.1M
- Amount sold
- $3.1M
- Placement agents
- Not applicable.
- First sale
- Jul 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$700KraisedApr 2026 · 11 investors · BiotechnologyRule 506(b)
▶$700KraisedApr 2026 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Chase LoPrioreDirector
- Sireesh AppajosyulaDirector
- Timothy BlockDirector
- Vincent LoPrioreExecutive Officer, Director
- Michael PurcellDirector
- Gary StetzExecutive Officer, Director
- Offering amount
- $700K
- Amount sold
- $700K
- Proceeds to insiders
- $700K
- First sale
- Apr 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.9MraisedJul 2024 · 7 investors · PharmaceuticalsRule 506(b)
▶$2.9MraisedJul 2024 · 7 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Kaouthar LbiatiDirector
- John CavanExecutive Officer
- Michael PurcellDirector
- Timothy BlockDirector
- John P. BrancaccioDirector
- Offering amount
- $2.9M
- Amount sold
- $2.9M
- Sales commissions
- $175K
- Placement agents
- A.G.P./Alliance Global Partners, Laidlaw & Company (UK) Ltd.
- First sale
- Jul 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5MraisedOct 2023 · 1 investors · PharmaceuticalsRule 506(b)
▶$5MraisedOct 2023 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Kaouthar LbiatiDirector
- Timothy BlockDirector
- Gary S. JacobDirector
- Anand ReddiDirector
- John CavanExecutive Officer
- Petrus WijngaardDirector
- Robert FosterExecutive Officer, Director
- John P. BrancaccioDirector
- Offering amount
- $5M
- Amount sold
- $5M
- Sales commissions
- $400K
- Placement agents
- A.G.P./Alliance Global Partners
- First sale
- Sep 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$20MraisedNov 2022 · 8 investors · BiotechnologyRule 506(b)
▶$20MraisedNov 2022 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gary S. JacobsDirector
- Timothy BlockDirector
- John CavanExecutive Officer
- John P. BrancaccioDirector
- Petrus WijngaardDirector
- Robert FosterExecutive Officer, Director
- Arnold LippaDirector
- Todd HobbsExecutive Officer
- Offering amount
- $20M
- Amount sold
- $20M
- Sales commissions
- $1M
- Placement agents
- A.G.P./ Alliance Global Partners
- First sale
- Nov 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.3MraisedMar 2019 · 1 investors · BiotechnologyRule 506(b)
▶$1.3MraisedMar 2019 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Timothy BlockDirector
- Thomas AdamsDirector
- John P. BrancaccioDirector
- Arnold LippaDirector
- John CavanExecutive Officer
- Gary S. JacobDirector
- Robert FosterExecutive Officer, Director
- Offering amount
- $1.3M
- Amount sold
- $1.3M
- First sale
- Mar 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$9MraisedOct 2014 · 1 investors · BiotechnologyRule 506(b)
▶$9MraisedOct 2014 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John BrancaccioDirector
- Bill HornungExecutive Officer
- Timothy BlockDirector
- Gary JacobDirector
- Christopher McGuiganDirector
- James SapirsteinExecutive Officer, Director
- Offering amount
- $12.5M
- Amount sold
- $9M
- First sale
- Oct 2014
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$4.7MraisedAug 2014 · 19 investors · BiotechnologyRule 506(b)
▶$4.7MraisedAug 2014 · 19 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Christopher McGuiganDirector
- Gary JacobDirector
- James SapirsteinExecutive Officer, Director
- Timothy BlockDirector
- Bill HornungExecutive Officer
- John BrancaccioDirector
- Offering amount
- $4.7M
- Amount sold
- $4.7M
- First sale
- Aug 2014
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 4
Alexion PharmaceuticalsAlexion is a biopharmaceutical company focused on research and development of treatments for rare diseases, serving rare disease patients and their families worldwide.
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Lexicon PharmaceuticalsLexicon Pharmaceuticals develops and commercializes pharmaceutical products, including the marketed drug INPEFA and drug candidates in clinical development such as sotagliflozin, pilavapadin, and LX9851, serving patients in need of treatments across various therapeutic areas.
Esperion TherapeuticsBiopharma developing HDL-C regulating therapies; listed 2000.
Companies working in the same space as Hepion Pharmaceuticals.
Frequently asked questions
- What does Hepion Pharmaceuticals do?
- Hepion Pharma is a pharmaceutical company with a therapeutic focus on hepatocellular carcinoma (liver cancer). This page is an investor presentations section with no substantive content available.
- How much funding has Hepion Pharmaceuticals raised?
- Hepion Pharmaceuticals has disclosed $49.9M raised across 9 rounds.
- Where is Hepion Pharmaceuticals headquartered?
- Hepion Pharmaceuticals is headquartered in Edison, US.